T1	Participants 57 186	patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy
T2	Participants 275 398	recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC) progressing after first-line platinum regimens
T3	Participants 871 1202	patients aged 18 years or older with histologically or cytologically confirmed HNSCC that was recurrent, metastatic, or both who had progressed on or after first-line platinum-based therapy, were not amenable for salvage surgery or radiotherapy, and who had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
T4	Participants 1204 1409	Previous treatment with more than one systemic regimen in this setting was not allowed; previous treatment with EGFR-targeted antibody therapy (but not EGFR-targeted tyrosine-kinase inhibitors) was allowed
T5	Participants 2302 2314	483 patients
